Respiratory Motion is on a roll, landing nearly $6 million in new funding and unveiling positive results from a clinical study of its ExSpiron non-invasive respiratory monitor.
The Waltham, Mass.-based hopes to close the Series B round with $8.8 million, having raised $5.8 million so far from lead investor Easton Capital and other existing investors. The funds are slated to support sales and marketing efforts for the ExSpiron system, the company said.
Respiratory Motion also publicly released findings from a landmark study, which landed the lead author a 1st-prize award during the 2013 Post Graduates Assembly in Anesthesiology conference in New York.
The 114-patient study reportedly found that post-operative monitoring with the ExSpiron system can help predict life-threatening complications. The data could help doctors make more informed decisions about which patients can safely receive opioid pain management after surgery.
Nearly 75% of the patients deemed at-risk by the ExSpiron monitor later exhibited symptoms of respiratory depression, and 97% of those the system deemed in the "safe zone" remained in recovery without incident following administration of pain-killers.
“More of my cardiac surgical patients succumbed to post-operative respiratory problems than cardiac complications," Respiratory Motion CEO Dr. Jenny Freeman, also a cardiothoracic surgeon, said in prepared remarks. "By modifying our treatment of these patients with lower dose opioid protocols or alternate pain management strategies, we hope to reduce the incidence of episodes of [respiratory depression] that manifest unpredictably hours later on hospital floors everywhere."
Chris Walker contributed to this report.